Trial Profile
Phase 3, open-label trial of pneumococcal 13-valent CRM197 vaccine conjugate [Prevnar 13] in children aged 5-10 years who had previously been vaccinated for the prevention of pneumococcal disease with pneumococcal 7-valent CRM197 vaccine conjugate [Prevnar], and vaccine-naive children and adolescents aged 10-17 years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2015
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- 14 Mar 2012 New trial record
- 12 Mar 2012 Results published in a Pfizer media release and presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD).